Non-Framed-Offered
BehavioralSubjects received information only and are offered the vaccine.
NCT Number: NCT00739752
The goal of this study is to evaluate two sets of interventions to increase acceptance of hepatitis B virus (HBV) vaccination in patients attending sexually transmitted disease (STD) clinics. The 1st set of interventions, with 3 levels, is based on message framing. The 3 levels are: 1. information only; 2. gain-framed message; and 3. loss-framed message. The 2nd set of interventions, with 2 levels, involves how the vaccine is recommended by the health care provider. The 2 levels are: 1. HBV vaccine offered; and 2. HBV vaccine recommended. The outcome of interest is1st dose acceptance.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Chicago Department of Public Health, Chicago, Illinois, United States
The goal of this study is to evaluate two sets of interventions to increase acceptance of hepatitis B virus (HBV) vaccination in patients attending sexually transmitted disease (STD) clinics. The 1st specific aim is to assess the effect of message-framing on vaccine acceptance. Framing theory suggests that positively framed messages (i.e., benefits of getting vaccine) are more effective than negatively framed messages (i.e., dangers of not getting vaccine) in stimulating preventive health behaviors. Research on Framing Theory and engagement in health behaviors suggests also that the effects may be moderated by other attitudinal factors, including perceived risk of the behavior and degree of involvement in the message. The 2nd aim is to evaluate the effect of provider-based interventions. Prior research suggests that recommendations by health providers are very important in patients' decisions regarding acceptance of health care procedures. Patients (18 years and older) will be recruited and followed from Chicago and Indianapolis STD clinics during routine medical visits. An audio computer-assisted self-interview (A-CASI) will cover demographics, risk behaviors, and perceived risk associated with vaccination. Subjects then will be randomized to receive a gain-framed, loss-framed, or information only message regarding HBV immunization (also delivered by A-CASI). Upon completion of the message-framing intervention, subjects will complete additional attitude questions via A-CASI. Upon completion of the A-CASI subjects will be randomly assigned to one of two provider intervention conditions: 1. vaccine offered or 2. vaccine recommended. For both conditions free HBV immunization will be provided by a nurse practitioner. Subsequently, postcard reminders will be sent and phone call reminders made for follow-up appointments for those receiving the first and second doses of vaccine. The primary outcome measure is HBV vaccination.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects received information only and are offered the vaccine.
Subjects receive information only and are recommended the vaccine.
Subjects receive gain-framed messages and are offered the vaccine.
Subjects receive gain-framed messages and are recommended the vaccine.
Subjects receive loss-framed messages and are offered the vaccine.
Subjects receive loss-framed messages and are recommended the vaccine.
Time frame: Day of research visit with 8 month follow-up
Mean Number of HBV vaccine doses received over an 8-month period, including the clinic visit. Count values ranged from 0 to 3 doses.
Indiana University
Other
Interventions to Increase HBV Vaccinations in STD Clinics
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03625258
Blood-Borne Infections, Communicable Diseases
Amiens, France
View Trial DetailsNCT03083821
Blood-Borne Infections, Communicable Diseases
Hachioji-shi, Tokyo, Japan
View Trial DetailsNCT04072211
Blood-Borne Infections, Communicable Diseases
Kalulushi, Copperbelt, Zambia
View Trial DetailsNCT03459521
Blood-Borne Infections, Communicable Diseases
Terrassa, Barcelona/Spain, Spain
View Trial Details